Sulforaphane ameliorates bisphenol A-induced hepatic lipid accumulation by inhibiting endoplasmic reticulum stress.
Level 5 - mechanism / opinion, no new human data
Preclinical laboratory study (in vitro human cell line and in vivo mouse model)
PubMed 36670177 · doi:10.1038/s41598-023-28395-5
What was done
The study investigated the role of endoplasmic reticulum (ER) stress in bisphenol A (BPA)-induced hepatic lipid accumulation and evaluated the protective effects of sulforaphane (SFN). Experiments were conducted using human LO2 hepatocyte cell lines and C57/BL6J mice. Measured outcomes included hepatic lipid accumulation, triglyceride levels, expression of lipogenesis-related genes, and ER stress pathway markers following treatment with BPA, the ER stress inhibitor 4-phenylbutyric acid, or SFN.
What was found
The abstract reports no numerical values, effect sizes, or variance estimates. Qualitatively, BPA increased lipid droplet count, triglyceride levels, mRNA expression of lipogenesis-related genes, and ER stress pathway activation. The ER stress inhibitor 4-phenylbutyric acid prevented these changes. SFN treatment reversed BPA-induced hepatic lipid metabolism alterations and reduced ER stress markers.
Why it matters
The study identifies ER stress inhibition as a potential mechanism by which sulforaphane mitigates BPA-induced liver lipid accumulation in preclinical systems.
Limits
Findings are strictly from in vitro cell lines and mouse models and cannot be directly translated to human clinical efficacy. The abstract provides no sample sizes, dosage regimens, exposure durations, or quantitative data.
Cited by
- supports Animal studies demonstrate that administration of sulforaphane protects against bisphenol A (BPA) toxicity.